



# Supplementary figure S1


**Figure S1A.** Basal expression of the antibodies by repetitive western blotting in PC9 and PC9GR cells




**Figure S1B.** Changes in expression of the antibodies with Gefitinib in PC9 and PC9GR cells




**Figure S1C.** Changes in expression of the antibodies with repetitive NF- $\kappa$ B inhibitor in PC9GR cells




**Figure S1C.** Changes in expression of the antibodies with repetitive NF- $\kappa$ B inhibitor in PC9GR cells (continued)




**Figure S1D.** Repetitive cell viability assay with NF- $\kappa$ B inhibition and AICDA knockdown in PC9GR cells



**Figure S1E.** Changes in expression of the antibodies with repetitive AICDA knockdown in PC9GR cells




**Figure S1E.** Changes in expression of the antibodies with repetitive AICDA knockdown in PC9GR cells (continued)






**Figure S1F.** Repetitive cell viability assay with EGFR inhibition (Gefitinib) and AICDA knockdown in PC9GR cells



**Figure S1G.** Repetitive cell viability assay with EGFR inhibition (G), NF-κB inhibition(B) and AICDA knockdown in PC9GR cells



**Figure S1H.** Changes in expression of the antibodies with EGFR inhibition (Gefitinib), NF- $\kappa$ B inhibition and AICDA knockdown in PC9GR cells

